| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA, Small Interfering | 80 | 2026 | 980 | 18.860 |
Why?
|
| RNA Interference | 33 | 2026 | 643 | 6.150 |
Why?
|
| Huntington Disease | 12 | 2026 | 159 | 4.480 |
Why?
|
| Oligonucleotides | 16 | 2026 | 229 | 4.460 |
Why?
|
| Huntingtin Protein | 15 | 2026 | 147 | 4.380 |
Why?
|
| Lipids | 8 | 2022 | 328 | 3.100 |
Why?
|
| Gene Silencing | 25 | 2026 | 430 | 2.970 |
Why?
|
| Oligonucleotides, Antisense | 13 | 2026 | 153 | 2.850 |
Why?
|
| RNA, Messenger | 21 | 2026 | 1575 | 2.240 |
Why?
|
| Animals | 73 | 2026 | 21324 | 2.230 |
Why?
|
| Nucleic Acids | 4 | 2024 | 66 | 2.220 |
Why?
|
| Mice | 50 | 2026 | 11105 | 2.160 |
Why?
|
| Central Nervous System | 3 | 2024 | 200 | 1.970 |
Why?
|
| Superoxide Dismutase-1 | 2 | 2025 | 148 | 1.650 |
Why?
|
| Drug Delivery Systems | 6 | 2024 | 333 | 1.600 |
Why?
|
| Extracellular Vesicles | 3 | 2018 | 45 | 1.590 |
Why?
|
| Myostatin | 2 | 2025 | 20 | 1.580 |
Why?
|
| Cholesterol | 7 | 2025 | 261 | 1.560 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 13 | 2026 | 281 | 1.430 |
Why?
|
| Acetylgalactosamine | 4 | 2026 | 13 | 1.430 |
Why?
|
| Trinucleotide Repeat Expansion | 4 | 2025 | 33 | 1.350 |
Why?
|
| RNAi Therapeutics | 4 | 2026 | 12 | 1.300 |
Why?
|
| Neurons | 6 | 2019 | 933 | 1.280 |
Why?
|
| Fatty Acids | 3 | 2020 | 198 | 1.270 |
Why?
|
| RNA-Induced Silencing Complex | 5 | 2026 | 72 | 1.260 |
Why?
|
| Humans | 82 | 2026 | 65121 | 1.190 |
Why?
|
| Gene Transfer Techniques | 3 | 2020 | 325 | 1.140 |
Why?
|
| HeLa Cells | 14 | 2019 | 541 | 1.020 |
Why?
|
| Tissue Distribution | 8 | 2024 | 293 | 1.010 |
Why?
|
| RNA | 9 | 2024 | 426 | 1.010 |
Why?
|
| Exosomes | 2 | 2018 | 53 | 0.990 |
Why?
|
| Hyperlipoproteinemia Type I | 1 | 2026 | 3 | 0.960 |
Why?
|
| Apolipoprotein C-III | 1 | 2026 | 7 | 0.960 |
Why?
|
| Organophosphorus Compounds | 3 | 2023 | 33 | 0.950 |
Why?
|
| Gene Expression Regulation | 7 | 2019 | 1630 | 0.940 |
Why?
|
| Myocardium | 2 | 2025 | 302 | 0.940 |
Why?
|
| Ribose | 1 | 2025 | 5 | 0.910 |
Why?
|
| Drug Design | 3 | 2024 | 137 | 0.910 |
Why?
|
| Species Specificity | 1 | 2024 | 339 | 0.810 |
Why?
|
| Apolipoproteins E | 4 | 2024 | 115 | 0.810 |
Why?
|
| MutS Homolog 3 Protein | 1 | 2023 | 4 | 0.790 |
Why?
|
| Muscle, Skeletal | 3 | 2025 | 784 | 0.780 |
Why?
|
| Cell Nucleus | 2 | 2024 | 630 | 0.760 |
Why?
|
| Liver | 12 | 2024 | 871 | 0.760 |
Why?
|
| Alzheimer Disease | 3 | 2024 | 765 | 0.750 |
Why?
|
| RNA, Double-Stranded | 5 | 2023 | 112 | 0.740 |
Why?
|
| Disease Models, Animal | 14 | 2026 | 2284 | 0.730 |
Why?
|
| High-Throughput Screening Assays | 3 | 2017 | 79 | 0.730 |
Why?
|
| Chemokine CXCL10 | 1 | 2022 | 56 | 0.720 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2022 | 25 | 0.710 |
Why?
|
| Organophosphonates | 2 | 2021 | 22 | 0.700 |
Why?
|
| DNA | 2 | 2023 | 858 | 0.680 |
Why?
|
| Cells, Cultured | 9 | 2018 | 2188 | 0.680 |
Why?
|
| Skin Diseases | 1 | 2022 | 80 | 0.680 |
Why?
|
| Genetic Therapy | 6 | 2023 | 838 | 0.660 |
Why?
|
| Phosphorothioate Oligonucleotides | 1 | 2020 | 10 | 0.660 |
Why?
|
| RNA Processing, Post-Transcriptional | 2 | 2018 | 103 | 0.650 |
Why?
|
| Mice, Inbred C57BL | 10 | 2026 | 3478 | 0.620 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2025 | 515 | 0.620 |
Why?
|
| Brain Neoplasms | 2 | 2024 | 318 | 0.600 |
Why?
|
| Kidney | 5 | 2019 | 451 | 0.590 |
Why?
|
| Nanoparticles | 2 | 2022 | 544 | 0.580 |
Why?
|
| Blood-Brain Barrier | 1 | 2018 | 87 | 0.540 |
Why?
|
| Phosphorylcholine | 4 | 2019 | 45 | 0.530 |
Why?
|
| Vinyl Compounds | 1 | 2017 | 5 | 0.530 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2017 | 100 | 0.530 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 108 | 0.530 |
Why?
|
| Parenchymal Tissue | 1 | 2017 | 5 | 0.520 |
Why?
|
| Brain | 4 | 2026 | 1604 | 0.510 |
Why?
|
| Base Pair Mismatch | 3 | 2024 | 36 | 0.500 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 35 | 0.500 |
Why?
|
| Nucleic Acid Conformation | 9 | 2017 | 243 | 0.500 |
Why?
|
| Epidermal Growth Factor | 1 | 2016 | 49 | 0.500 |
Why?
|
| Exons | 4 | 2026 | 205 | 0.490 |
Why?
|
| Mice, Transgenic | 6 | 2026 | 1287 | 0.490 |
Why?
|
| Dystrophin | 3 | 2025 | 30 | 0.490 |
Why?
|
| Hepatocytes | 4 | 2026 | 222 | 0.490 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 285 | 0.480 |
Why?
|
| Drug Discovery | 1 | 2017 | 96 | 0.480 |
Why?
|
| Guanabenz | 1 | 2015 | 3 | 0.470 |
Why?
|
| Heart | 3 | 2025 | 297 | 0.470 |
Why?
|
| Vesicular Transport Proteins | 1 | 2016 | 117 | 0.470 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2024 | 203 | 0.460 |
Why?
|
| Muscular Dystrophy, Duchenne | 3 | 2025 | 45 | 0.460 |
Why?
|
| Endosomes | 1 | 2016 | 180 | 0.460 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 203 | 0.440 |
Why?
|
| Transfection | 9 | 2008 | 701 | 0.420 |
Why?
|
| Prodrugs | 1 | 2014 | 36 | 0.420 |
Why?
|
| RNA, Catalytic | 5 | 2005 | 21 | 0.410 |
Why?
|
| Base Sequence | 13 | 2018 | 1329 | 0.410 |
Why?
|
| Docosahexaenoic Acids | 3 | 2018 | 31 | 0.400 |
Why?
|
| MicroRNAs | 6 | 2024 | 710 | 0.400 |
Why?
|
| Mutation | 6 | 2024 | 2658 | 0.390 |
Why?
|
| 3' Untranslated Regions | 3 | 2012 | 95 | 0.380 |
Why?
|
| Sheep | 2 | 2024 | 189 | 0.380 |
Why?
|
| Cell Line | 10 | 2024 | 2023 | 0.380 |
Why?
|
| Endothelial Cells | 2 | 2026 | 208 | 0.380 |
Why?
|
| Gene Editing | 3 | 2024 | 328 | 0.380 |
Why?
|
| Corpus Striatum | 3 | 2023 | 98 | 0.370 |
Why?
|
| Lung | 3 | 2023 | 962 | 0.360 |
Why?
|
| Response Elements | 1 | 2012 | 44 | 0.360 |
Why?
|
| Biological Transport | 3 | 2018 | 292 | 0.360 |
Why?
|
| RNA Stability | 3 | 2025 | 104 | 0.350 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2024 | 92 | 0.350 |
Why?
|
| Heart Diseases | 2 | 2026 | 223 | 0.340 |
Why?
|
| Gene Regulatory Networks | 2 | 2012 | 160 | 0.340 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 128 | 0.340 |
Why?
|
| Female | 14 | 2026 | 34013 | 0.340 |
Why?
|
| Gene Knock-In Techniques | 3 | 2026 | 48 | 0.330 |
Why?
|
| Reperfusion Injury | 2 | 2022 | 57 | 0.320 |
Why?
|
| Endocytosis | 3 | 2019 | 152 | 0.310 |
Why?
|
| Rats | 3 | 2024 | 1994 | 0.310 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2008 | 297 | 0.300 |
Why?
|
| Base Pairing | 2 | 2006 | 44 | 0.290 |
Why?
|
| Gene Expression Profiling | 4 | 2008 | 794 | 0.280 |
Why?
|
| Cell Line, Tumor | 9 | 2026 | 1566 | 0.280 |
Why?
|
| Liver Transplantation | 2 | 2022 | 220 | 0.280 |
Why?
|
| Transcription, Genetic | 4 | 2026 | 907 | 0.270 |
Why?
|
| Trinucleotide Repeats | 2 | 2025 | 18 | 0.270 |
Why?
|
| Genome, Human | 2 | 2021 | 237 | 0.270 |
Why?
|
| Neoplasms | 1 | 2018 | 1367 | 0.270 |
Why?
|
| Melanoma | 4 | 2021 | 333 | 0.260 |
Why?
|
| Genes, Reporter | 2 | 2025 | 257 | 0.260 |
Why?
|
| Structure-Activity Relationship | 3 | 2019 | 354 | 0.260 |
Why?
|
| Cell Culture Techniques | 2 | 2018 | 195 | 0.250 |
Why?
|
| Sequence Alignment | 2 | 2006 | 300 | 0.250 |
Why?
|
| Prion Proteins | 1 | 2026 | 7 | 0.240 |
Why?
|
| Mitogen-Activated Protein Kinase 13 | 1 | 2026 | 2 | 0.240 |
Why?
|
| Prion Diseases | 1 | 2026 | 13 | 0.240 |
Why?
|
| RNA, Neoplasm | 1 | 2006 | 36 | 0.240 |
Why?
|
| Prions | 1 | 2026 | 27 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2026 | 25 | 0.240 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2026 | 37 | 0.240 |
Why?
|
| Drug Approval | 1 | 2026 | 28 | 0.240 |
Why?
|
| Albumins | 1 | 2026 | 43 | 0.230 |
Why?
|
| Doxorubicin | 1 | 2026 | 98 | 0.230 |
Why?
|
| Gene Targeting | 2 | 2005 | 77 | 0.230 |
Why?
|
| Interferons | 1 | 2006 | 74 | 0.230 |
Why?
|
| Myocytes, Cardiac | 1 | 2026 | 123 | 0.230 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2026 | 61 | 0.230 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2025 | 37 | 0.230 |
Why?
|
| Genomic Instability | 1 | 2025 | 59 | 0.220 |
Why?
|
| alpha-Synuclein | 1 | 2025 | 38 | 0.220 |
Why?
|
| Phosphates | 1 | 2026 | 104 | 0.220 |
Why?
|
| Thionucleotides | 4 | 2005 | 39 | 0.220 |
Why?
|
| Amyloid beta-Peptides | 2 | 2024 | 321 | 0.220 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2025 | 76 | 0.220 |
Why?
|
| Endoribonucleases | 1 | 2005 | 57 | 0.220 |
Why?
|
| Diphosphates | 3 | 1993 | 12 | 0.220 |
Why?
|
| Antagomirs | 1 | 2024 | 5 | 0.210 |
Why?
|
| RNA Helicases | 1 | 2005 | 98 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 4 | 2018 | 426 | 0.210 |
Why?
|
| Amyloidogenic Proteins | 1 | 2024 | 13 | 0.210 |
Why?
|
| Codon, Nonsense | 1 | 2024 | 62 | 0.210 |
Why?
|
| tau Proteins | 1 | 2025 | 210 | 0.210 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 81 | 0.210 |
Why?
|
| Apolipoprotein E4 | 1 | 2024 | 46 | 0.200 |
Why?
|
| Superoxide Dismutase | 1 | 2025 | 222 | 0.200 |
Why?
|
| Motor Neurons | 1 | 2025 | 218 | 0.200 |
Why?
|
| Alleles | 2 | 2022 | 453 | 0.200 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2023 | 20 | 0.200 |
Why?
|
| Genomics | 1 | 2007 | 384 | 0.200 |
Why?
|
| Genetic Engineering | 2 | 2004 | 113 | 0.200 |
Why?
|
| Amyloid | 1 | 2024 | 73 | 0.200 |
Why?
|
| Neostriatum | 1 | 2023 | 26 | 0.200 |
Why?
|
| Dogs | 1 | 2024 | 315 | 0.200 |
Why?
|
| Phenylalanine-tRNA Ligase | 2 | 1993 | 2 | 0.190 |
Why?
|
| RNA, Transfer, Phe | 2 | 1993 | 3 | 0.190 |
Why?
|
| Organ Preservation | 2 | 2022 | 22 | 0.190 |
Why?
|
| Gene Expression | 2 | 2016 | 852 | 0.190 |
Why?
|
| Perfusion | 2 | 2022 | 75 | 0.190 |
Why?
|
| Lysine-tRNA Ligase | 2 | 1992 | 3 | 0.190 |
Why?
|
| Sequence Analysis, RNA | 1 | 2004 | 180 | 0.190 |
Why?
|
| Molecular Sequence Data | 6 | 2008 | 1979 | 0.190 |
Why?
|
| Skin | 1 | 2026 | 422 | 0.190 |
Why?
|
| Glioblastoma | 1 | 2024 | 161 | 0.180 |
Why?
|
| Databases, Factual | 1 | 2006 | 882 | 0.180 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2022 | 38 | 0.180 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 39 | 0.180 |
Why?
|
| Drug Administration Routes | 1 | 2021 | 22 | 0.180 |
Why?
|
| Liposomes | 1 | 2022 | 116 | 0.180 |
Why?
|
| Cyclophilins | 2 | 2016 | 12 | 0.180 |
Why?
|
| Bulbo-Spinal Atrophy, X-Linked | 1 | 2021 | 1 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2005 | 104 | 0.170 |
Why?
|
| Vitiligo | 1 | 2023 | 120 | 0.170 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 42 | 0.170 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 312 | 0.170 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 51 | 0.170 |
Why?
|
| Cell Survival | 4 | 2006 | 587 | 0.170 |
Why?
|
| Cells | 1 | 2021 | 32 | 0.170 |
Why?
|
| Receptors, Androgen | 1 | 2021 | 86 | 0.160 |
Why?
|
| Muscular Diseases | 1 | 2020 | 50 | 0.160 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 117 | 0.160 |
Why?
|
| Fibroblasts | 1 | 2022 | 422 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2023 | 321 | 0.160 |
Why?
|
| Breast Neoplasms | 2 | 2026 | 1222 | 0.160 |
Why?
|
| Interferon-gamma | 1 | 2022 | 574 | 0.160 |
Why?
|
| Synaptic Vesicles | 1 | 2019 | 25 | 0.150 |
Why?
|
| Male | 7 | 2025 | 31039 | 0.150 |
Why?
|
| Thermodynamics | 4 | 2018 | 196 | 0.150 |
Why?
|
| Kinetics | 7 | 2005 | 759 | 0.150 |
Why?
|
| Receptors, LDL | 1 | 2019 | 35 | 0.150 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2019 | 17 | 0.150 |
Why?
|
| Carbocyanines | 1 | 2019 | 31 | 0.150 |
Why?
|
| Lipoproteins, LDL | 1 | 2019 | 48 | 0.140 |
Why?
|
| Chitosan | 1 | 2019 | 87 | 0.140 |
Why?
|
| Umbilical Cord | 1 | 2018 | 9 | 0.140 |
Why?
|
| Spheroids, Cellular | 1 | 2018 | 28 | 0.140 |
Why?
|
| Mannitol | 1 | 2018 | 15 | 0.140 |
Why?
|
| Blood Proteins | 1 | 2019 | 84 | 0.140 |
Why?
|
| Propylene Glycols | 1 | 2018 | 9 | 0.140 |
Why?
|
| Neuropeptides | 1 | 2019 | 81 | 0.140 |
Why?
|
| Biomedical Research | 2 | 2024 | 262 | 0.140 |
Why?
|
| Carotid Arteries | 1 | 2018 | 64 | 0.140 |
Why?
|
| RNA, Transfer | 2 | 2024 | 93 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2018 | 161 | 0.140 |
Why?
|
| Aptamers, Nucleotide | 1 | 2018 | 28 | 0.140 |
Why?
|
| Molecular Structure | 1 | 2019 | 316 | 0.140 |
Why?
|
| Peptide Nucleic Acids | 1 | 2017 | 17 | 0.130 |
Why?
|
| Organ Specificity | 1 | 2018 | 198 | 0.130 |
Why?
|
| Astrocytes | 1 | 2018 | 123 | 0.130 |
Why?
|
| Proteome | 1 | 2018 | 152 | 0.130 |
Why?
|
| Mice, Inbred Strains | 1 | 2017 | 185 | 0.130 |
Why?
|
| Exoribonucleases | 1 | 2017 | 30 | 0.130 |
Why?
|
| Fluorescent Dyes | 1 | 2019 | 202 | 0.130 |
Why?
|
| Acylation | 6 | 1999 | 16 | 0.130 |
Why?
|
| Triazoles | 1 | 2017 | 63 | 0.130 |
Why?
|
| Serine | 1 | 2017 | 90 | 0.130 |
Why?
|
| Drug Stability | 1 | 2017 | 144 | 0.130 |
Why?
|
| Genetic Vectors | 3 | 2018 | 917 | 0.120 |
Why?
|
| COS Cells | 1 | 2016 | 180 | 0.120 |
Why?
|
| Transferrin | 1 | 2016 | 70 | 0.120 |
Why?
|
| Cell Differentiation | 2 | 2019 | 1386 | 0.120 |
Why?
|
| Poly U | 2 | 1992 | 2 | 0.120 |
Why?
|
| Models, Molecular | 3 | 2017 | 1162 | 0.120 |
Why?
|
| Phosphorylation | 2 | 2017 | 962 | 0.120 |
Why?
|
| Biotechnology | 1 | 2016 | 38 | 0.120 |
Why?
|
| Cell Movement | 2 | 2026 | 480 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 401 | 0.110 |
Why?
|
| Small Molecule Libraries | 1 | 2015 | 57 | 0.110 |
Why?
|
| Mice, Inbred mdx | 2 | 2025 | 17 | 0.110 |
Why?
|
| Forecasting | 1 | 2016 | 230 | 0.110 |
Why?
|
| Janus Kinase 1 | 2 | 2026 | 17 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 1225 | 0.110 |
Why?
|
| Phenotype | 4 | 2021 | 1232 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 524 | 0.110 |
Why?
|
| Peptides | 1 | 2018 | 588 | 0.100 |
Why?
|
| Internet | 2 | 2008 | 468 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2026 | 1036 | 0.100 |
Why?
|
| Fibrosis | 2 | 2026 | 172 | 0.100 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2013 | 35 | 0.100 |
Why?
|
| Anticodon | 1 | 1992 | 12 | 0.100 |
Why?
|
| Tyrosine-tRNA Ligase | 1 | 1992 | 2 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 1698 | 0.100 |
Why?
|
| Mice, Obese | 2 | 2024 | 80 | 0.100 |
Why?
|
| Retina | 1 | 2013 | 132 | 0.090 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 2 | 2018 | 16 | 0.090 |
Why?
|
| RNA, Bacterial | 1 | 1992 | 73 | 0.090 |
Why?
|
| Saccharomyces cerevisiae | 3 | 1999 | 570 | 0.090 |
Why?
|
| Virus Replication | 2 | 2004 | 323 | 0.090 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2018 | 111 | 0.090 |
Why?
|
| Escherichia coli | 2 | 1993 | 714 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2026 | 583 | 0.080 |
Why?
|
| Enzyme Inhibitors | 3 | 2007 | 367 | 0.080 |
Why?
|
| Down-Regulation | 3 | 2026 | 324 | 0.080 |
Why?
|
| HEK293 Cells | 2 | 2024 | 615 | 0.080 |
Why?
|
| Magnesium | 3 | 2004 | 54 | 0.070 |
Why?
|
| Models, Genetic | 2 | 2008 | 266 | 0.070 |
Why?
|
| Substrate Specificity | 2 | 2005 | 341 | 0.070 |
Why?
|
| Catalysis | 3 | 2004 | 163 | 0.070 |
Why?
|
| Rabbits | 3 | 2013 | 338 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 2 | 2022 | 428 | 0.070 |
Why?
|
| Time Factors | 5 | 2013 | 3762 | 0.070 |
Why?
|
| Genetic Complementation Test | 1 | 2008 | 67 | 0.070 |
Why?
|
| RNA, Antisense | 2 | 2007 | 50 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 673 | 0.070 |
Why?
|
| Microarray Analysis | 1 | 2008 | 64 | 0.070 |
Why?
|
| Plasmids | 3 | 2003 | 294 | 0.070 |
Why?
|
| Apoptosis | 4 | 2005 | 1100 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2008 | 141 | 0.070 |
Why?
|
| Genes, BRCA1 | 1 | 2007 | 17 | 0.060 |
Why?
|
| RNA, Untranslated | 1 | 2007 | 105 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2005 | 218 | 0.060 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2006 | 6 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2017 | 5785 | 0.060 |
Why?
|
| Injections, Intradermal | 1 | 2026 | 12 | 0.060 |
Why?
|
| Cardiotoxicity | 1 | 2026 | 18 | 0.060 |
Why?
|
| Silicon | 1 | 2006 | 17 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2008 | 410 | 0.060 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2026 | 84 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2026 | 113 | 0.060 |
Why?
|
| Ventricular Remodeling | 1 | 2026 | 95 | 0.060 |
Why?
|
| Zinc Fingers | 1 | 2025 | 105 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2004 | 266 | 0.060 |
Why?
|
| Manganese | 1 | 2005 | 20 | 0.060 |
Why?
|
| RNA Splicing | 1 | 2026 | 167 | 0.050 |
Why?
|
| Swine | 1 | 2026 | 394 | 0.050 |
Why?
|
| RNA, Transfer, Lys | 1 | 2004 | 1 | 0.050 |
Why?
|
| Ribonuclease III | 1 | 2005 | 87 | 0.050 |
Why?
|
| Gentamicins | 1 | 2024 | 24 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2026 | 234 | 0.050 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2024 | 12 | 0.050 |
Why?
|
| Prostatic Neoplasms | 2 | 2006 | 493 | 0.050 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2005 | 131 | 0.050 |
Why?
|
| Diptera | 1 | 2004 | 5 | 0.050 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2004 | 21 | 0.050 |
Why?
|
| Collagen Type I | 1 | 2024 | 44 | 0.050 |
Why?
|
| Mixed Function Oxygenases | 1 | 2004 | 19 | 0.050 |
Why?
|
| Congresses as Topic | 1 | 2024 | 76 | 0.050 |
Why?
|
| DNA Primers | 1 | 2004 | 301 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2026 | 321 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2019 | 3149 | 0.050 |
Why?
|
| Proteins | 3 | 2004 | 764 | 0.050 |
Why?
|
| RNA, Plant | 1 | 2003 | 13 | 0.050 |
Why?
|
| Hepatic Stellate Cells | 1 | 2024 | 25 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2024 | 287 | 0.050 |
Why?
|
| Luciferases | 1 | 2004 | 107 | 0.050 |
Why?
|
| Computational Biology | 1 | 2006 | 367 | 0.050 |
Why?
|
| Collagen | 1 | 2024 | 135 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 178 | 0.050 |
Why?
|
| Software | 1 | 2007 | 400 | 0.050 |
Why?
|
| Cystic Fibrosis | 1 | 2024 | 126 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2004 | 127 | 0.050 |
Why?
|
| RNA Precursors | 1 | 2003 | 78 | 0.050 |
Why?
|
| Amino Acid Motifs | 1 | 2003 | 156 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 1163 | 0.050 |
Why?
|
| Chemical Engineering | 1 | 2022 | 9 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2005 | 644 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2005 | 394 | 0.050 |
Why?
|
| Amines | 2 | 1992 | 31 | 0.050 |
Why?
|
| HIV-1 | 2 | 2004 | 706 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 182 | 0.050 |
Why?
|
| Trachea | 1 | 2022 | 83 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2005 | 391 | 0.040 |
Why?
|
| Diacylglycerol O-Acyltransferase | 1 | 2021 | 11 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2024 | 332 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2023 | 247 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 856 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2003 | 145 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2021 | 301 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2021 | 202 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2026 | 2155 | 0.040 |
Why?
|
| Dementia | 1 | 2024 | 280 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2003 | 791 | 0.040 |
Why?
|
| Goals | 1 | 2021 | 96 | 0.040 |
Why?
|
| Triglycerides | 1 | 2021 | 248 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 182 | 0.040 |
Why?
|
| Drosophila | 1 | 2003 | 480 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 2019 | 27 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 408 | 0.040 |
Why?
|
| Aspartate-tRNA Ligase | 1 | 1999 | 1 | 0.040 |
Why?
|
| RNA, Transfer, Asp | 1 | 1999 | 1 | 0.040 |
Why?
|
| Binding Sites | 2 | 2017 | 921 | 0.040 |
Why?
|
| Algorithms | 1 | 2005 | 1048 | 0.040 |
Why?
|
| Extracorporeal Circulation | 1 | 2019 | 6 | 0.040 |
Why?
|
| Protein Binding | 1 | 2003 | 1639 | 0.040 |
Why?
|
| Solid-Phase Synthesis Techniques | 1 | 2018 | 3 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2021 | 531 | 0.030 |
Why?
|
| Models, Biological | 1 | 2003 | 1192 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2019 | 115 | 0.030 |
Why?
|
| Macromolecular Substances | 1 | 2018 | 162 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2018 | 116 | 0.030 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2018 | 99 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2017 | 115 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 345 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2003 | 706 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2018 | 506 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1187 | 0.030 |
Why?
|
| Caspases | 2 | 2005 | 176 | 0.030 |
Why?
|
| Cytoplasm | 2 | 2005 | 283 | 0.030 |
Why?
|
| Genome, Viral | 2 | 2004 | 144 | 0.020 |
Why?
|
| Intravitreal Injections | 1 | 2013 | 54 | 0.020 |
Why?
|
| Eye Diseases | 1 | 2013 | 37 | 0.020 |
Why?
|
| Inorganic Pyrophosphatase | 1 | 1993 | 1 | 0.020 |
Why?
|
| Obesity | 1 | 2021 | 1273 | 0.020 |
Why?
|
| Pyrophosphatases | 1 | 1993 | 11 | 0.020 |
Why?
|
| Yeasts | 1 | 1992 | 47 | 0.020 |
Why?
|
| Cattle | 1 | 1992 | 320 | 0.020 |
Why?
|
| Mitochondria | 2 | 2005 | 409 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 5609 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4810 | 0.020 |
Why?
|
| Adolescent | 1 | 2021 | 6305 | 0.020 |
Why?
|
| Integrin beta1 | 1 | 2008 | 32 | 0.020 |
Why?
|
| beta Catenin | 1 | 2008 | 99 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2008 | 95 | 0.020 |
Why?
|
| United States | 1 | 2021 | 8094 | 0.020 |
Why?
|
| Wound Healing | 1 | 2008 | 193 | 0.020 |
Why?
|
| Actins | 1 | 2008 | 264 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 2007 | 39 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2005 | 8 | 0.010 |
Why?
|
| Framycetin | 1 | 2005 | 1 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2005 | 28 | 0.010 |
Why?
|
| Thapsigargin | 1 | 2004 | 17 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2005 | 24 | 0.010 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2005 | 23 | 0.010 |
Why?
|
| Magnesium Chloride | 1 | 2004 | 6 | 0.010 |
Why?
|
| Aged | 1 | 2021 | 14955 | 0.010 |
Why?
|
| Taxoids | 1 | 2004 | 25 | 0.010 |
Why?
|
| Cations, Divalent | 1 | 2004 | 25 | 0.010 |
Why?
|
| Schistosoma | 1 | 2004 | 3 | 0.010 |
Why?
|
| Ribonuclease H | 1 | 2004 | 19 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2004 | 45 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2005 | 138 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2005 | 108 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 542 | 0.010 |
Why?
|
| Catalase | 1 | 2004 | 21 | 0.010 |
Why?
|
| Protein Kinase C-alpha | 1 | 2004 | 17 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2004 | 40 | 0.010 |
Why?
|
| Vitamin K Epoxide Reductases | 1 | 2004 | 3 | 0.010 |
Why?
|
| Cisplatin | 1 | 2004 | 147 | 0.010 |
Why?
|
| Clathrin | 1 | 2004 | 23 | 0.010 |
Why?
|
| Spodoptera | 1 | 2004 | 27 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2004 | 145 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2004 | 23 | 0.010 |
Why?
|
| Adult | 1 | 2021 | 17356 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 491 | 0.010 |
Why?
|
| Middle Aged | 1 | 2021 | 18264 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2004 | 102 | 0.010 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2004 | 83 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2004 | 231 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2004 | 464 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 152 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 295 | 0.010 |
Why?
|
| Electroporation | 1 | 2003 | 36 | 0.010 |
Why?
|
| Warfarin | 1 | 2004 | 125 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2004 | 237 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2004 | 154 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 185 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 449 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 215 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 513 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 460 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 662 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2004 | 398 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 343 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 610 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2005 | 718 | 0.010 |
Why?
|
| Molecular Mimicry | 1 | 1999 | 31 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1999 | 251 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 384 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 875 | 0.010 |
Why?
|